BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 8759358)

  • 21. Studies on transfer of primate membrane-associated complement inhibitors from recipient blood to porcine donor organs.
    Kroshus TJ; Bolman RM; Dalmasso AP
    Transplant Proc; 1996 Apr; 28(2):601-2. PubMed ID: 8623295
    [No Abstract]   [Full Text] [Related]  

  • 22. Uveal melanoma: no expression of HLA-G.
    Hurks HM; Valter MM; Wilson L; Hilgert I; van den Elsen PJ; Jager MJ
    Invest Ophthalmol Vis Sci; 2001 Dec; 42(13):3081-4. PubMed ID: 11726606
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The complement regulatory proteins CD55 (decay accelerating factor) and CD59 are expressed on the inner acrosomal membrane of human spermatozoa as well as CD46 (membrane cofactor protein).
    Cummerson JA; Flanagan BF; Spiller DG; Johnson PM
    Immunology; 2006 Jul; 118(3):333-42. PubMed ID: 16827894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complement regulatory proteins in the salivary glands and saliva of Sjögren's syndrome patients and healthy subjects.
    Cuida M; Legler DW; Eidsheim M; Jonsson R
    Clin Exp Rheumatol; 1997; 15(6):615-23. PubMed ID: 9444417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59.
    Schmitz J; Zimmer JP; Kluxen B; Aries S; Bögel M; Gigli I; Schmitz H
    J Clin Invest; 1995 Sep; 96(3):1520-6. PubMed ID: 7544808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential expression of the complement regulatory proteins in the human eye.
    Bora NS; Gobleman CL; Atkinson JP; Pepose JS; Kaplan HJ
    Invest Ophthalmol Vis Sci; 1993 Dec; 34(13):3579-84. PubMed ID: 7505007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of transfected MACIF (CD59) on complement-mediated swine endothelial cell lysis, compared with those of membrane cofactor protein (CD46) and decay-accelerating factor (CD55).
    Miyagawa S; Shirakura R; Nakata S; Izutani H; Matsuda H; Iwata K; Nagasawa S; Terado A; Hatanaka M; Matsumoto M
    Transplant Proc; 1995 Feb; 27(1):328-9. PubMed ID: 7533401
    [No Abstract]   [Full Text] [Related]  

  • 28. Relationship between natural killer cell susceptibility and metastasis of human uveal melanoma cells in a murine model.
    Ma D; Luyten GP; Luider TM; Niederkorn JY
    Invest Ophthalmol Vis Sci; 1995 Feb; 36(2):435-41. PubMed ID: 7843912
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Porcine complement regulators protect aortic smooth muscle cells poorly against human complement-induced lysis and proliferation: consequences for xenotransplantation.
    Capey S; van den Berg CW
    Xenotransplantation; 2005 May; 12(3):217-26. PubMed ID: 15807772
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Susceptibility of human trophoblast to killing by human complement and the role of the complement regulatory proteins.
    Tedesco F; Narchi G; Radillo O; Meri S; Ferrone S; Betterle C
    J Immunol; 1993 Aug; 151(3):1562-70. PubMed ID: 7687635
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Coordinate functions of multiple complement regulating molecules, CD46, CD55, and CD59.
    Loveland BE; Szokolai K; Johnstone RW; McKenzie IF
    Transplant Proc; 1994 Jun; 26(3):1070-1. PubMed ID: 7518104
    [No Abstract]   [Full Text] [Related]  

  • 32. Use of complement regulators, CD35, CD46, CD55, and CD59, on leukocytes as markers for diagnosis of viral and bacterial infections.
    Nuutila J; Jalava-Karvinen P; Hohenthal U; Kotilainen P; Pelliniemi TT; Nikoskelainen J; Lilius EM
    Hum Immunol; 2013 May; 74(5):522-30. PubMed ID: 23376460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The role of membrane glycoproteins CD46, CD55 and CD59 in protection of tumor cells against complement lysis].
    Wojnicz D; Bar J; Jankowski S
    Postepy Hig Med Dosw; 2002; 56(5):603-16. PubMed ID: 12587428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aberrant expression of membrane cofactor protein and decay-accelerating factor in the endothelium of patients with systemic sclerosis. A possible mechanism of vascular damage.
    Venneker GT; van den Hoogen FH; Boerbooms AM; Bos JD; Asghar SS
    Lab Invest; 1994 Jun; 70(6):830-5. PubMed ID: 7516986
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Susceptibility of HIV-1 plasma virus to complement-mediated lysis. Evidence for a role in clearance of virus in vivo.
    Sullivan BL; Knopoff EJ; Saifuddin M; Takefman DM; Saarloos MN; Sha BE; Spear GT
    J Immunol; 1996 Aug; 157(4):1791-8. PubMed ID: 8759769
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction.
    Saifuddin M; Hedayati T; Atkinson JP; Holguin MH; Parker CJ; Spear GT
    J Gen Virol; 1997 Aug; 78 ( Pt 8)():1907-11. PubMed ID: 9266986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complement regulatory proteins at the feto-maternal interface during human placental development: distribution of CD59 by comparison with membrane cofactor protein (CD46) and decay accelerating factor (CD55).
    Holmes CH; Simpson KL; Okada H; Okada N; Wainwright SD; Purcell DF; Houlihan JM
    Eur J Immunol; 1992 Jun; 22(6):1579-85. PubMed ID: 1376264
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression and function of multiple regulators of complement activation in autoimmune thyroid disease.
    Tandon N; Yan SL; Morgan BP; Weetman AP
    Immunology; 1994 Apr; 81(4):643-7. PubMed ID: 7518800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protection of rat endothelial cells from primate complement-mediated lysis by expression of human CD59 and/or decay-accelerating factor.
    Charreau B; Cassard A; Tesson L; Le Mauff B; Navenot JM; Blanchard D; Lublin D; Soulillou JP; Anegon I
    Transplantation; 1994 Dec; 58(11):1222-9. PubMed ID: 7527603
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma.
    Weng WK; Levy R
    Blood; 2001 Sep; 98(5):1352-7. PubMed ID: 11520782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.